Literature DB >> 10702398

Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.

V Wallenius1, M Hisaoka, K Helou, G Levan, N Mandahl, J M Meis-Kindblom, L G Kindblom, J O Jansson.   

Abstract

Enhanced hepatocyte growth factor (HGF) receptor (Met) signaling has been suggested to play an important role in the development and progression of various epithelial and nonepithelial tumors. N-terminally truncated forms of the HGF receptor have been shown to be constitutively activated and tumorigenic in animal experiments. In the present study, 102 benign and malignant human musculoskeletal tumors were examined for expression of the HGF receptor by Western blotting and/or immunohistochemistry. A clear predominance of HGF receptor expression was seen in malignant as compared to benign tumors (Western blotting, P < 0.001; immunohistochemistry, P < 0.02). For the first time we show HGF receptor expression in the following four tumor types: dermatofibrosarcoma protuberans, clear cell sarcoma of tendons, malignant primitive neuroectodermal tumor, and benign fibrous histiocytoma. In three cases of sarcoma with high HGF receptor expression by Western blotting, we found indications of a short 85-kd N-terminally truncated HGF receptor that was tyrosine phosphorylated and located in the cytoplasm. Although fragments of this length were seen in 18 of 65 tumors, most were not tyrosine-phosphorylated. Northern blotting revealed only the 7.5-kb full-length HGF receptor transcript, suggesting that the 85-kd fragment is generated by an alternative initiation of translation or by proteolytic cleavage. Southern blotting detected no amplification of the Hgfr/Met gene in the 35 tumors examined, in contrast to our recent report of Hgfr/Met gene amplification in 7, 12-dimethylbenz(a)anthracene (DMBA)-induced rat sarcomas. The present data suggest that the locally aggressive and malignant properties of human mesenchymal tumors maybe related, in part, to high levels of full-length HGF receptors, and in some cases to the occurrence of N-terminally truncated HGF receptors, activated independently of HGF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702398      PMCID: PMC1876854          DOI: 10.1016/S0002-9440(10)64950-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

1.  Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas.

Authors:  R Ferracini; M Olivero; M F Di Renzo; M Martano; C De Giovanni; P Nanni; G Basso; K Scotlandi; P L Lollini; P M Comoglio
Journal:  Oncogene       Date:  1996-04-18       Impact factor: 9.867

2.  Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene.

Authors:  S Giordano; Z Zhen; E Medico; G Gaudino; F Galimi; P M Comoglio
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

3.  Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors.

Authors:  K Scotlandi; N Baldini; M Oliviero; M F Di Renzo; M Martano; M Serra; M C Manara; P M Comoglio; R Ferracini
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

4.  Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors.

Authors:  T J Liang; A E Reid; R Xavier; R D Cardiff; T C Wang
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

5.  Generation of a truncated hepatocyte growth factor receptor in the endoplasmic reticulum.

Authors:  T Crepaldi; M Prat; S Giordano; E Medico; P M Comoglio
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

6.  Hepatocyte growth factor is a mitogen for Schwann cells and is present in neurofibromas.

Authors:  A Krasnoselsky; M J Massay; M C DeFrances; G Michalopoulos; R Zarnegar; N Ratner
Journal:  J Neurosci       Date:  1994-12       Impact factor: 6.167

Review 7.  The Met-HGF/SF autocrine signaling mechanism is involved in sarcomagenesis.

Authors:  J Cortner; G F Vande Woude; S Rong
Journal:  EXS       Date:  1995

8.  Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site.

Authors:  C C Lee; K M Yamada
Journal:  J Biol Chem       Date:  1994-07-29       Impact factor: 5.157

9.  Amplification of the MET gene in glioma.

Authors:  U Fischer; H W Müller; H P Sattler; K Feiden; K D Zang; E Meese
Journal:  Genes Chromosomes Cancer       Date:  1995-01       Impact factor: 5.006

10.  The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit.

Authors:  R Ferracini; M F Di Renzo; K Scotlandi; N Baldini; M Olivero; P Lollini; O Cremona; M Campanacci; P M Comoglio
Journal:  Oncogene       Date:  1995-02-16       Impact factor: 9.867

View more
  25 in total

Review 1.  Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.

Authors:  Alla Danilkovitch-Miagkova; Berton Zbar
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.

Authors:  Mads Lerdrup; Silas Bruun; Michael V Grandal; Kirstine Roepstorff; Malene M Kristensen; Anette M Hommelgaard; Bo van Deurs
Journal:  Mol Biol Cell       Date:  2007-07-11       Impact factor: 4.138

3.  Accuracy of regenerating motor neurons: influence of diffusion in denervated nerve.

Authors:  R D Madison; G A Robinson
Journal:  Neuroscience       Date:  2014-05-15       Impact factor: 3.590

Review 4.  Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.

Authors:  Blanca Homet Moreno; Elena Garralda Cabanas; Ricardo Hitt
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

Review 5.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

6.  Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer.

Authors:  Erika M Wolff; Hyang-Min Byun; Han F Han; Shikhar Sharma; Peter W Nichols; Kimberly D Siegmund; Allen S Yang; Peter A Jones; Gangning Liang
Journal:  PLoS Genet       Date:  2010-04-22       Impact factor: 5.917

7.  Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-Met gene.

Authors:  Mehrnoosh Saghizadeh; Andrei A Kramerov; Fu-Shin X Yu; Maria G Castro; Alexander V Ljubimov
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-20       Impact factor: 4.799

8.  Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density.

Authors:  Cornelius Kuhnen; Thomas Muehlberger; Maria Honsel; Edina Tolnay; Hans Ulrich Steinau; Klaus-Michael Müller
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-09       Impact factor: 4.553

9.  Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.

Authors:  Ian J Davis; Andrew W McFadden; Yixiang Zhang; Angela Coxon; Teresa L Burgess; Andrew J Wagner; David E Fisher
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

10.  Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis.

Authors:  M Lieveld; E Bodson; G De Boeck; B Nouman; A M Cleton-Jansen; E Korsching; M S Benassi; P Picci; G Sys; B Poffyn; N A Athanasou; P C W Hogendoorn; R G Forsyth
Journal:  Virchows Arch       Date:  2014-10-11       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.